Almac Group Introduce Flexible Clinical Trial Direct To Patient Solution

Almac are pleased to announce the launch of their novel “Direct to Patient” shipping service for clinical trials recognising the shift in market trends to introduce as many efficiencies as possible into the management of clinical trials and the supply chain.

The Direct to Patient offering further enhances the existing clinical trial distribution service provided by Almac by co-ordinating all clinical trial (including temperature and non-temperature controlled) material shipments from clinical sites directly to patient’s homes throughout the US and Canada. Due diligence has been performed to ensure adherence with US federal, state and Canadian regulations.

This service offers clinical trial patients enhanced flexibility as it works around their personal convenience and improves the patient experience by reducing on-site clinic visits. In addition patients no longer have to travel to clinical sites for all of their visits thereby reducing associated costs and drop-out rates.

The Direct to Patient service implemented by Almac is in response to increasing sponsor demand and enables trial sponsors to move closer to the patients participating in the trials, regardless of their proximity to study sites.

Donna Christopher, Global VP Operations at Almac commented “Our innovative direct to patient solution offers sponsors a flexible and cost effective approach to conduct their clinical trials which improves patient experience, compliance and efficiency whilst reducing the burden associated with patient retention. We firmly believe this addresses significant challenges currently experienced by our sponsors and Almac are delighted to offer this as part of our established clinical supply solutions.”

Find out more about Almac’s Direct to Patient service – http://almacgroup.com/clinical-trial-supply/global-distribution-and-supply-chain-management/direct-to-patient

About Almac Group

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

Visit www.almacgroup.com, e-mail media@almacgroup.com

Help employers find you! Check out all the jobs and post your resume.

Back to news